Focal demyelination is induced in the optic nerve using lysolecithin microinjection. Visual evoked potentials are recorded via skull electrodes implanted over the visual cortex to examine the signal conduction along the visual pathway in vivo. This protocol details the surgical procedures underlying electrode implantation and optic nerve microinjection.
The visual evoked potential (VEP) recording is widely used in clinical practice to assess the severity of optic neuritis in its acute phase, and to monitor the disease course in the follow-up period. Changes in the VEP parameters closely correlate with pathological damage in the optic nerve. This protocol provides a detailed description about the rodent model of optic nerve microinjection, in which a partial demyelination lesion is produced in the optic nerve. VEP recording techniques are also discussed. Using skull implanted electrodes, we are able to acquire reproducible intra-session and between-session VEP traces. VEPs can be recorded on individual animals over a period of time to assess the functional changes in the optic nerve longitudinally. The optic nerve demyelination model, in conjunction with the VEP recording protocol, provides a tool to investigate the disease processes associated with demyelination and remyelination, and can potentially be employed to evaluate the effects of new remyelinating drugs or neuroprotective therapies.
Optic neuritis is one of the most common form of optic neuropathy, causing complete or partial loss of vision1. Histologically, it is featured by inflammatory demyelination, retinal ganglion cell axonal loss and varying degrees of remyelination in the optic nerve2. Optic neuritis is usually the manifest onset of multiple sclerosis. The visual evoked potential (VEP) is a non-invasive tool for investigating the function of the visual system. It reflects the post-retinal function from the retina to the primary visual cortex and is affected in many optic nerve disease conditions3. The VEP has been predominantly used in optic neuritis patients to assess the integrity of the visual pathway4.
The latency of VEP, which reflects the velocity of signal conduction along the visual pathway, is considered to be an accurate measurement of the level of myelin associated changes in the optic nerve5; while the amplitude of VEP is believed to be closely correlated with axonal damage of the retinal ganglion cells (RGC)6. This hypothesis has been fairly well established using the rat model of lysolecithin-induced optic nerve demyelination5.
Here, we explicate a comprehensive protocol of optic nerve microinjection technique in rodents, which can minimise the surgical manipulation-related damage to the nerve per se as well as to the adjacent tissues such as extraocular muscles and blood vessels. Also, the skull electrode implantation surgery has been described for VEP recording in animals7. The VEP recordings can be repeatedly carried out on animals over a period of time to assess demyelination/remyelination related changes as well as impact on axonal integrity in the optic nerve.
Ethics Statement: All procedures involving animals were conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and the guidelines of the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and were approved by the Animal Ethics Committee of Macquarie University.
1. VEP Electrode Implantation
2. Optic Nerve Injection
3. VEP Recording
4. Tissue Preparation and Histology
Reproducible intra-sessional VEP traces are shown in Figure 1 and a significant delay in N1 latency can be seen after the optic nerve injection. Partial optic nerve lesions of demyelination can be observed on histological sections using Luxol fast blue staining5. Figure 2 shows a representative section with a small focal demyelinated lesion in the centre of the optic nerve. Note that cross section does not represent total volume of lesion. The demyelinated area can be measured on each consecutive cross-section of the nerve to deduce the lesion volume by using three-dimensional reconstruction. We have demonstrated a strong correlation between latency delay and lesion volume using this model in our previous studies and there was no VEP latency delay in the saline-injected controls5.
It is believed that early VEP components following the flash illumination are more stable7 and principally affected by the excitation of the primary visual cortex via retino-geniculate fibres. Our study has shown that N1 delay has the strongest linear relationship with demyelination in the optic nerve5. Hence, we recommend that N1 latency should be used for data analysis and for longitudinal VEP monitoring in assessing the impact of remyelinating therapies. The amplitude of VEP, although more variable compared to the latency, is more indicative of function of the axons in the optic nerve6. Electroencephalogram-based scaling can be considered for amplitude analysis9.
Figure 1. VEP delay after optic nerve injection. Representative VEP traces from an individual rat before and 2 days after the optic nerve microinjection (0.8 µl lysolecithin). VEP recordings were repeated on the each day (intra-sessional traces are shown in the same colour) to demonstrate the reproducibility of this VEP recording protocol. (vertical scale bar: 10 µV; horizontal scale bar: 10 msec). Please click here to view a larger version of this figure.
Figure 2. Demyelination in the optic nerve. Representative cross-section of the optic nerve from a rat after lysolecithin microinjection. The myelin component is stained blue by using luxol fast blue. A small focal lesion of demyelination can be seen in the centre of the section. Demyelinated area can be measured on longitudinal serial cross-sections to estimate the lesion volume in a three-dimensional scale. Please click here to view a larger version of this figure.
The optic nerve is very susceptible to mechanical damage. Optic nerve crush injury over a duration of 1 s can lead to about 75% loss of RGC over a period of 2 weeks10. Therefore, extreme care is required while performing the surgical procedures. According to the authors’ experience, it is much better to adapt a blunt dissection approach to expose and make way through the tissues around the optic nerve along the orientation of the nerve, rather than penetrating in a perpendicular orientation to the optic nerve. Also, the dura and arachnoid mater should be unwraped longitudinally to avoid any axotomy-like damage to the RGC axons. Evan’s blue is usually used to facilitate the microinjection, as presence of the dye makes the nerve light blue in colour at the injection site.
The reproducibility of VEP recording is critical for this experiment. Different types of anaesthetics and the depth of anaesthesia can affect the VEP waveforms11. We do not recommend using inhaled isoflurane anaesthesia for the VEP study, as isoflurane can lead to burst suppress on the electroencephalogram response12, probably due to GABAergic activity, resulting in more variable VEP traces13. Combination of ketamine/medetomidine anaesthesia provides stable anaesthesia that can quickly be reversed by administration of an alpha receptor antagonist such as atipamazole (2.5 mg/kg i.p). Body temperature can also have a significant impact on the speed of nerve conduction, especially in demyelinated nerves. Temperature-dependant changes in visual evoked potentials have been observed in rat VEPs and latencies were observed to be significantly longer as body temperature was lowered14,15. Hence, it is important to maintain a uniform body temperature using a homoeothermic blanket system during the VEP recordings.
Also, it is important to understand that the pathogenesis of lysolecithin-induced demyelination differs from that in optic neuritis or multiple sclerosis. Lysolecithin-induced demyelination results from the detergent like action of the toxin upon myelin lipids rather than immune-mediated inflammatory reaction, which is usually seen in the real disease scenarios16. If the study aims to investigate the mechanisms of demyelination/axonal damage in multiple sclerosis, an immune-mediated demyelination model, such as experimental autoimmune encephalomyelitis (EAE)17, should be considered. The advantage of using the toxin-induced demyelination model is that a focal lesion in the optic nerve can be produced and monitored longitudinally. In contrast to the brain lesions, the effects of demyelinated lesions on the optic nerve are more clinically apparent and measureable (lesion size can be accurately determined by VEPs or MRI imaging). Although remyelination in the optic nerve appeared to be not as pronounced as that observed previously in the case of spinal cord18, this optic nerve injection model, in conjunction with the VEP recording technique, is able to provide a superior tool to monitor the process of demyelination and remyelination in vivo, and to potentially evaluate new remyelinating therapies.
The authors have nothing to disclose.
This study was supported by the Ophthalmic Research Institute of Australia (ORIA). We thank Prof. Algis Vingrys and Dr. Bang Bui, University of Melbourne, for initially helping us to develop the VEP recording technique.
Ketamine 100 mg/ml (Ketamil) | Troy Laboratories | AC 116 | |
Medetomidine 1 mg/ml (Domitor) | Pfizer | sc-204073 | |
Tropicamide 1.0% (Mydriacyl) | Alcon | sc-202371 | |
Homoeothermic blanket system | Harvard Apparatus | NC9203819 | |
Impedance meter | Grass | F-EZM5 | |
Screw electrodes | Micro Fasteners | M1.0×3mm Csk Slot M/T 304 S/S | |
Subdermal needle electrodes | Grass | F-E3M-72 | |
Rapid Repair | DeguDent GmbH | ||
Light-emitting diode | Nichia | NSPG300A | |
Bioamplifier | CWE, Inc. | BMA-400 | |
CED system | Cambridge Electronic Design, Ltd. | Power1401 | |
Hamilton syringe | Hamilton | 87930 | |
Lysolecithin | Sigma | L4129 | |
Evan’s blue | Sigma | E2129 |